GRI Bio (NASDAQ: GRI) — Perfil da empresa, notícias e dados financeiros
GRI Bio is a clinical-stage biotech targeting NKT cells for treatments of inflammatory diseases like pulmonary fibrosis.
GRI GRI Bio
Perfil da empresa
GRI Bio
GRI Bio (NASDAQ:GRI) is a clinical-stage biotech taking a new approach to inflammatory diseases. They target NKT cells, immune system regulators, to interrupt disease progression. Their lead program, GRI-0621, is a potential treatment for idiopathic pulmonary fibrosis, a serious lung condition. With a library of over 500 compounds, GRI Bio has the potential for a growing pipeline of treatments.
Resumo
Public USParticipação acionária
2009Ano de fundação
4Funcionários
La Jolla, United StatesSede
Carregando mapa...
Presença global
Operações
Todos os locais
United States
Produtos e/ou serviços de GRI Bio
- Developing therapies: They focus on treatments for inflammatory, fibrotic, and autoimmune diseases.
- NKT cell targeting: Their approach targets Natural Killer T (NKT) cells to regulate the immune system.
- Drug pipeline: They have a pipeline of drug candidates, with GRI-0621 being the most advanced.
- Pre-clinical and clinical trials: Their drugs are currently in pre-clinical and clinical trial phases, not yet available for commercial use.
- Compound library: They have a library of over 500 proprietary compounds which could fuel future drug development.
equipe executiva do GRI Bio
- W. Marc HertzCo-Founder, CEO, President & Director
- Vipin Kumar ChaturvediCo-Founder & Chief Scientific Officer
- Leanne M. KellyCFO & Corporate Secretary
- Albert AgroCo-Founder & Chief Medical Officer
Últimas notícias sobre a GRI Bio
Principais indicadores financeiros
Resultados divulgados pela GRI Bio, em USD.
- Cap. de mercado
- 3,6 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -14.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -12 mi | -12 mi | |
| 22,5 mi | -8,2 mi | -8,2 mi | |
| 21,8 mi | -11,4 mi | -13 mi | |
| 0 | -2,2 mi | -3,2 mi |